Literature DB >> 2803319

Membrane-associated cathepsin L: a role in metastasis of melanomas.

J Rozhin1, R L Wade, K V Honn, B F Sloane.   

Abstract

Subcellular distribution of cathepsin L, the major protein released by transformed or ras transfected fibroblasts, was examined in murine liver, murine B16 amelanotic melanoma and human A2058 melanoma after sequential differential and Percoll density gradient centrifugation. In both murine and human melanomas, cathepsin L activity was found to be enriched in plasma membrane fractions; cathepsin L in these fractions was in both native and acid activatable forms. Plasma membrane fractions from B16 melanoma subpopulations of "low" and "high" metastatic potential were assayed for activity of cathepsin L and of heat stable endogenous inhibitors. The relative specific activity of cathepsin L was 7-fold greater in the subpopulation of "high" metastatic potential, whereas cysteine proteinase inhibitory activity was 5-fold less. Since cathepsin L can degrade intact basement membrane, this membrane-associated cathepsin L may well contribute to metastatic spread of melanomas.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2803319     DOI: 10.1016/0006-291x(89)91755-5

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  21 in total

Review 1.  Non-tissue factor procoagulants in cancer cells.

Authors:  S G Gordon; M Chelladurai
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264

2.  Proteolytic processing and glycosylation of cathepsin B. The role of the primary structure of the latent precursor and of the carbohydrate moiety for cell-type-specific molecular forms of the enzyme.

Authors:  L Mach; K Stüwe; A Hagen; C Ballaun; J Glössl
Journal:  Biochem J       Date:  1992-03-01       Impact factor: 3.857

3.  An approach to computer-aided inhibitor design: application to cathepsin L.

Authors:  S Sudarsanam; G D Virca; C J March; S Srinivasan
Journal:  J Comput Aided Mol Des       Date:  1992-06       Impact factor: 3.686

Review 4.  Cathepsin L targeting in cancer treatment.

Authors:  Dhivya R Sudhan; Dietmar W Siemann
Journal:  Pharmacol Ther       Date:  2015-08-20       Impact factor: 12.310

Review 5.  Proteases and proteolysis in the lysosome.

Authors:  P Bohley; P O Seglen
Journal:  Experientia       Date:  1992-02-15

Review 6.  Cysteinyl cathepsins in cardiovascular diseases.

Authors:  Xian Zhang; Songyuan Luo; Minjie Wang; Guo-Ping Shi
Journal:  Biochim Biophys Acta Proteins Proteom       Date:  2020-01-09       Impact factor: 3.036

7.  Expression of cysteine protease inhibitors in human gliomas and meningiomas.

Authors:  M Sivaparvathi; I McCutcheon; R Sawaya; G L Nicolson; J S Rao
Journal:  Clin Exp Metastasis       Date:  1996-09       Impact factor: 5.150

8.  Biochemical and immunohistochemical analysis of cathepsins B, H, L and D in human melanocytic tumours.

Authors:  T Kageshita; A Yoshii; T Kimura; K Maruo; T Ono; M Himeno; Y Nishimura
Journal:  Arch Dermatol Res       Date:  1995       Impact factor: 3.017

9.  Cloning and characterization of anti-cathepsin L single chain variable fragment whose expression inhibits procathepsin L secretion in human melanoma cells.

Authors:  Nathalie Guillaume-Rousselet; Didier Jean; Raymond Frade
Journal:  Biochem J       Date:  2002-10-01       Impact factor: 3.857

10.  Collagenolytic cysteine proteinases of bone tissue. Cathepsin B, (pro)cathepsin L and a cathepsin L-like 70 kDa proteinase.

Authors:  J M Delaissé; P Ledent; G Vaes
Journal:  Biochem J       Date:  1991-10-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.